Kasim Kutay is the CEO of Copenhagen-based Novo Holdings A/S. Novo Holdings A/S is the holding and investment company of the Novo Group, with total assets of approximately $60 billion (as at December 31, 2017). Novo Holdings A/S's largest holdings are its controlling interests in Novo Nordisk, the world’s leading diabetes pharma company, and in Novozymes, the world’s leading bio-industrials company.
Prior to joining Novo Holdings A/S, Kasim Kutay had 26 years of experience in investment banking with a focus on the healthcare sector. He started his career at Morgan Stanley, where he spent 18 years advising mainly healthcare companies. In 2009, Kasim Kutay joined Moelis & Company, a leading global independent investment bank. He was Co-head of Europe at Moelis & Company and also served on the bank's Management Committee. He joined Novo Holdings A/S as CEO in 2016.
Kasim Kutay is a British citizen. He is fluent in English, French and Arabic. He holds a BSc in Economics and an MSc in Politics of the World Economy from the London School of Economics and Political Science.